Anavex Life Sciences Challenges the Basic Assumptions In Treating Alzheimer’s Disease

The company’s lead drug candidate for Alzheimer’s Disease (AD), ANAVEX 2-73, has successfully completed a Phase 1 single ascending dose clinical trial.

Read more »